A Proof-of-Concept Study Evaluating EOM613 in COVID-19 Infected Patients With Severe Symptoms
A Proof-of-Concept Study Evaluating Safety, Tolerability, and Preliminary Efficacy of EOM613 in COVID-19 Infected Patients With Severe Symptoms
Sponsor: EOM Pharmaceuticals
Listed as NCT05212532, this PHASE1 trial focuses on COVID-19 Acute Respiratory Distress Syndrome and COVID-19 Pneumonia and remains ongoing. Sponsored by EOM Pharmaceuticals, it has been updated 4 times since 2021, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Feb 2024 — Jul 2024 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Feb 2022 — Feb 2024 [monthly]
Recruiting PHASE1
First recorded
Aug 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- EOM Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .